The mechanisms that drive responses to PD-1-blocking immunotherapy in some but not all patients have been puzzling. A new study suggests that the balance of PD-1 expression levels between CD8+ T cells and Treg cells might provide an answer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers
Molecular Medicine Open Access 14 February 2024
-
The inter-link of ageing, cancer and immunity: findings from real-world retrospective study
Immunity & Ageing Open Access 15 December 2023
-
Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer
Molecular Diagnosis & Therapy Open Access 31 October 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Debbie Maizels/Springer Nature
References
Kumagai, S. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0769-3 (2020).
Miyara, M. et al. Immunity 30, 899–911 (2009).
Wing, J. B., Tanaka, A. & Sakaguchi, S. Immunity 50, 302–316 (2019).
Hsieh, C.-S. et al. Immunity 21, 267–277 (2004).
Fife, B. T. et al. J. Exp. Med. 203, 2737–2747 (2006).
Zhang, B., Chikuma, S., Hori, S., Fagarasan, S. & Honjo, T. Proc. Natl Acad. Sci. USA 113, 8490–8495 (2016).
Francisco, L. M. et al. J. Exp. Med. 206, 3015–3029 (2009).
Patsoukis, N. et al. Nat. Commun. 6, 6692 (2015).
Shi, L. Z. et al. J. Exp. Med. 208, 1367–1376 (2011).
Haxhinasto, S., Mathis, D. & Benoist, C. J. Exp. Med. 205, 565–574 (2008).
Delgoffe, G. M. et al. Immunity 30, 832–844 (2009).
Ali, K. et al. Nature 510, 407–411 (2014).
Acknowledgements
This work was supported by the National Institutes of Health awards RO1CA212605, RO1CA238263 and RO1CA229784 (V.A.B.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V.A.B. has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. The authors declare no other competing interests.
Rights and permissions
About this article
Cite this article
Aksoylar, HI., Boussiotis, V.A. PD-1+ Treg cells: a foe in cancer immunotherapy?. Nat Immunol 21, 1311–1312 (2020). https://doi.org/10.1038/s41590-020-0801-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-020-0801-7
This article is cited by
-
Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers
Molecular Medicine (2024)
-
Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition
Medical Oncology (2024)
-
Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer
Molecular Diagnosis & Therapy (2024)
-
The inter-link of ageing, cancer and immunity: findings from real-world retrospective study
Immunity & Ageing (2023)
-
Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
Cancer Nanotechnology (2023)
